A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer

Dades bibliogràfiques
Autors principals:	Vallis, K, Reilly, R, Scollard, D, Merante, P, Freeman, M, Lockwood, G, Sabate, K, Brade, A
Format:	Conference item
Publicat:	2008

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
per: Vallis, K, et al.
Publicat: (2014)

A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
per: Vallis, K, et al.
Publicat: (2005)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
per: Reilly, R, et al.
Publicat: (2006)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
per: Hu, M, et al.
Publicat: (2007)

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
per: Wang, J, et al.
Publicat: (2001)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
per: Bailey, K, et al.
Publicat: (2007)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
per: Chen, P, et al.
Publicat: (2003)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
per: Reilly, R, et al.
Publicat: (2004)

Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
per: Chen, P, et al.
Publicat: (2002)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
per: Cai, Z, et al.
Publicat: (2008)

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
per: Reilly, R, et al.
Publicat: (2000)

In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR
per: Reilly, R, et al.
Publicat: (2000)

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Co-administration of Targeting Ligand
per: Song, L, et al.
Publicat: (2017)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
per: Cornelissen, B, et al.
Publicat: (2009)

Moleculary targeted auger electron radiation therapy for breast cancer: A clinical trial.
per: Vallis, K, et al.
Publicat: (2004)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
per: Costantini, D, et al.
Publicat: (2010)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
per: Cornelissen, B, et al.
Publicat: (2011)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
per: Costantini, D, et al.
Publicat: (2008)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
per: Costantini, D, et al.
Publicat: (2010)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
per: Jacob J. Adashek, et al.
Publicat: (2020-08-01)

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
per: Reilly, R, et al.
Publicat: (2000)

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software.
per: Cai, Z, et al.
Publicat: (2009)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
per: Cornelissen, B, et al.
Publicat: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
per: Costantini, D, et al.
Publicat: (2007)

123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).
per: Hu, M, et al.
Publicat: (2007)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
per: Cornelissen, B, et al.
Publicat: (2006)

Development of an epidermal growth factor derivative with EGFR blocking activity.
per: Clara Panosa, et al.
Publicat: (2013-01-01)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
per: McLarty, K, et al.
Publicat: (2009)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
per: McLarty, K, et al.
Publicat: (2009)

111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells
per: Gill, M, et al.
Publicat: (2018)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
per: Alexey A. Larionov
Publicat: (2018-04-01)

Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy.
per: Rayan, G, et al.
Publicat: (2003)

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
per: Komal Jhaveri, et al.
Publicat: (2017-08-01)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
per: Zhe-Yu Hu, et al.
Publicat: (2023-06-01)

The Antitumorigenic Function of EGFR in Metastatic Breast Cancer is Regulated by Expression of Mig6
per: Michael K. Wendt, et al.
Publicat: (2015-01-01)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
per: Chen, P, et al.
Publicat: (2001)

Sphingolipid metabolism during epidermal barrier development in mice
per: Thomas Doering, et al.
Publicat: (2002-10-01)

Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.
per: Wang, J, et al.
Publicat: (2003)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
per: Reilly, R, et al.
Publicat: (2002)

EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
per: Song, L, et al.
Publicat: (2016)

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer

Ítems similars

Ítems similars